Eli Lilly Quarterly Income Statement
NYSE: LLYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Eli Lilly revenue and earnings
In the quarter ended Jun 30, 2026, Eli Lilly generated $22.97 billion in revenue, up 47.7% from the same quarter a year earlier. Net income was $7.09 billion (+25.3% year over year), for a net margin of 30.9% versus a median of 34.4% in the prior 5 quarters. Gross margin was 85.8% (up from 84.3%).
Diluted earnings per share came in at $7.94, up from $6.29.
Summary generated from market data by MetaCap's automated system. Methodology
Eli Lilly income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.97B | 19.80B | 19.29B | 17.60B | 15.56B | 12.73B | 13.53B | 11.44B | 11.30B | 8.77B | 9.35B | 9.50B |
| Revenue growth (YoY) | +47.67% | +55.54% | +42.55% | +53.87% | +37.65% | +45.18% | +44.69% | +20.43% | +35.98% | +25.98% | +28.10% | +36.84% |
| Cost of Revenue | 3.27B | 3.58B | 3.37B | 3.01B | 2.45B | 2.23B | 2.40B | 2.17B | 2.17B | 1.67B | 1.79B | 1.86B |
| Gross Profit | 19.71B | 16.22B | 15.92B | 14.59B | 13.11B | 10.50B | 11.13B | 9.27B | 9.13B | 7.09B | 7.57B | 7.64B |
| Research & Development | 3.82B | 3.51B | 3.80B | 3.47B | 3.34B | 2.73B | 3.02B | 2.73B | 2.71B | 2.52B | 2.56B | 2.41B |
| Selling, General & Admin | 3.43B | 2.93B | 3.13B | 2.74B | 2.75B | 2.47B | 2.42B | 2.10B | 2.12B | 1.95B | 1.93B | 1.80B |
| Interest Expense | — | — | 222.60M | 179.60M | 249.00M | 243.70M | 225.10M | 192.70M | 183.60M | 179.60M | 138.20M | 124.60M |
| Other Income (Expense) | 269.00M | -65.00M | -108.30M | -133.10M | -90.00M | -239.00M | -110.50M | 62.00M | -197.60M | 27.10M | 121.30M | -23.20M |
| Pretax Income | 9.25B | 8.85B | 8.27B | 7.23B | 6.78B | 3.46B | 5.04B | 1.59B | 3.52B | 2.54B | 2.51B | 427.20M |
| Income Tax | 2.15B | 1.45B | 1.63B | 1.65B | 1.12B | 697.00M | 628.50M | 618.10M | 550.20M | 293.20M | 318.90M | 484.60M |
| Net Income | 7.09B | 7.40B | 6.64B | 5.58B | 5.66B | 2.76B | 4.41B | 970.30M | 2.97B | 2.24B | 2.19B | -57.40M |
| Net Income growth (YoY) | +25.33% | +168.07% | +50.52% | +475.34% | +90.80% | +23.01% | +101.43% | — | +68.27% | +66.77% | +12.98% | -103.95% |
| EPS (Basic) | 7.95 | 8.27 | 7.41 | 6.22 | 6.30 | 3.07 | 4.90 | 1.08 | 3.29 | 2.49 | 2.43 | -0.06 |
| EPS (Diluted) | 7.94 | 8.26 | 7.39 | 6.21 | 6.29 | 3.06 | 4.88 | 1.07 | 3.28 | 2.48 | 2.42 | -0.06 |
| Shares Outstanding (Basic) | 892.40M | 894.50M | — | 896.90M | 897.90M | 898.70M | — | 901.00M | 900.90M | 900.80M | — | 899.80M |
| Shares Outstanding (Diluted) | 893.70M | 895.90M | — | 898.80M | 899.80M | 900.60M | — | 905.00M | 904.20M | 903.80M | — | 899.80M |
| Gross Margin | 85.78% | 81.93% | 82.52% | 82.91% | 84.27% | 82.52% | 82.24% | 81.02% | 80.80% | 80.91% | 80.89% | 80.42% |
| Net Margin | 30.88% | 37.36% | 34.41% | 31.72% | 36.39% | 21.67% | 32.59% | 8.48% | 26.25% | 25.58% | 23.41% | -60.00% |
This table shows 12 quarterly periods of Eli Lilly's income statement, from Q2 2026 back to Q3 2023, across 17 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow LLY's reporting calendar. What is a income statement?